 Connection
David Simpson to Clinical Trials as Topic
This is a "connection" page, showing publications David Simpson has written about Clinical Trials as Topic.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.492 |
|
|
|
-
Simpson DM. Clinical trials of botulinum toxin in the treatment of spasticity. Muscle Nerve Suppl. 1997; 6:S169-75.
Score: 0.101
-
H?ke A, Simpson DM, Freeman R. Designing innovative therapies for neuropathic pain: preclinical and early clinical development challenges. J Peripher Nerv Syst. 2014 Oct; 19 Suppl 2:S28-9.
Score: 0.086
-
Attal N, Bouhassira D, Baron R, Dostrovsky J, Dworkin RH, Finnerup N, Gourlay G, Haanpaa M, Raja S, Rice AS, Simpson D, Treede RD. Assessing symptom profiles in neuropathic pain clinical trials: can it improve outcome? Eur J Pain. 2011 May; 15(5):441-3.
Score: 0.068
-
Dworkin RH, Turk DC, Peirce-Sandner S, Baron R, Bellamy N, Burke LB, Chappell A, Chartier K, Cleeland CS, Costello A, Cowan P, Dimitrova R, Ellenberg S, Farrar JT, French JA, Gilron I, Hertz S, Jadad AR, Jay GW, Kalliom?ki J, Katz NP, Kerns RD, Manning DC, McDermott MP, McGrath PJ, Narayana A, Porter L, Quessy S, Rappaport BA, Rauschkolb C, Reeve BB, Rhodes T, Sampaio C, Simpson DM, Stauffer JW, Stucki G, Tobias J, White RE, Witter J. Research design considerations for confirmatory chronic pain clinical trials: IMMPACT recommendations. Pain. 2010 May; 149(2):177-193.
Score: 0.063
-
Simpson DM, Gracies JM, Graham HK, Miyasaki JM, Naumann M, Russman B, Simpson LL, So Y. Assessment: Botulinum neurotoxin for the treatment of spasticity (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2008 May 06; 70(19):1691-8.
Score: 0.055
-
Simpson DM, Blitzer A, Brashear A, Comella C, Dubinsky R, Hallett M, Jankovic J, Karp B, Ludlow CL, Miyasaki JM, Naumann M, So Y. Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2008 May 06; 70(19):1699-706.
Score: 0.055
-
Dorfman D, Dalton A, Khan A, Markarian Y, Scarano A, Cansino M, Wulff E, Simpson D. Treatment of painful distal sensory polyneuropathy in HIV-infected patients with a topical agent: results of an open-label trial of 5% lidocaine gel. AIDS. 1999 Aug 20; 13(12):1589-90.
Score: 0.030
-
Dobkin BH, Landau WM, Sahrmann S, Thomas Thach W, Simpson DM, Gracies JM, Graham K, Hallett M, Miyasaki J, Naumann M, Russman B, Simpson L, So Y. Assessment: botulinum neurotoxin for the treatment of spasticity (an evidence-based review). Neurology. 2009 Sep 01; 73(9):736; author reply 737-8.
Score: 0.015
-
Naumann M, So Y, Argoff CE, Childers MK, Dykstra DD, Gronseth GS, Jabbari B, Kaufmann HC, Schurch B, Silberstein SD, Simpson DM. Assessment: Botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2008 May 06; 70(19):1707-14.
Score: 0.014
-
Lee A, Simpson D, Whitfield A, Scott DB. Postoperative analgesia by continuous extradural infusion of bupivacaine and diamorphine. Br J Anaesth. 1988 Jun; 60(7):845-50.
Score: 0.003
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|